Healthcare — Institutional Ownership & Hedge Fund Activity
Track hedge fund buying and selling activity in Healthcare stocks based on SEC 13F filings for Q3 2026.
Most Bought Healthcare Stocks
| # | Stock | Company | Funds Buying | Net $ Change |
|---|
| 1 | LLY | Eli Lilly and Company | 53 | $-230.7M |
| 2 | JNJ | Johnson & Johnson | 43 | $-43.7M |
| 3 | ABBV | AbbVie Inc. | 40 | +$144.1M |
| 4 | MRK | Merck & Co., Inc. | 35 | +$42.6M |
| 5 | MDT | Medtronic Plc | 33 | +$66.5B |
| 6 | ABT | Abbott Laboratories | 32 | $-64.1B |
| 7 | PFE | Pfizer Inc. | 28 | +$66.1B |
| 8 | SYK | Stryker Corporation | 28 | +$54.1M |
| 9 | AMGN | Amgen Inc. | 27 | +$29.7M |
| 10 | UNH | UnitedHealth Group Incorporated | 27 | +$35.1M |
| 11 | ISRG | Intuitive Surgical, Inc. | 26 | $-21.4M |
| 12 | GILD | Gilead Sciences, Inc. | 25 | +$32.1M |
| 13 | TMO | Thermo Fisher Scientific Inc. | 23 | +$154.3M |
| 14 | BMY | Bristol-Myers Squibb Company | 21 | $-8.9B |
| 15 | DHR | Danaher Corporation | 20 | $-41.7M |
| 16 | MCK | McKesson Corporation | 18 | +$26.1M |
| 17 | VRTX | Vertex Pharmaceuticals Incorporated | 18 | +$125.3M |
| 18 | AZN | AstraZeneca PLC | 16 | $-249.3M |
| 19 | CVS | CVS Health Corp. | 15 | +$185.1B |
| 20 | GSK | GSK plc | 14 | $-14.4B |
Most Sold Healthcare Stocks
| # | Stock | Company | Funds Selling | Net $ Change |
|---|
| 1 | JNJ | Johnson & Johnson | 56 | $-43.7M |
| 2 | MRK | Merck & Co., Inc. | 50 | +$42.6M |
| 3 | ABBV | AbbVie Inc. | 48 | +$144.1M |
| 4 | PFE | Pfizer Inc. | 41 | +$66.1B |
| 5 | ABT | Abbott Laboratories | 38 | $-64.1B |
| 6 | LLY | Eli Lilly and Company | 38 | $-230.7M |
| 7 | AMGN | Amgen Inc. | 33 | +$29.7M |
| 8 | SYK | Stryker Corporation | 29 | +$54.1M |
| 9 | TMO | Thermo Fisher Scientific Inc. | 29 | +$154.3M |
| 10 | BMY | Bristol-Myers Squibb Company | 27 | $-8.9B |
| 11 | UNH | UnitedHealth Group Incorporated | 25 | +$35.1M |
| 12 | CI | Cigna Corporation | 21 | $-4.8M |
| 13 | CVS | CVS Health Corp. | 21 | +$185.1B |
| 14 | DHR | Danaher Corporation | 21 | $-41.7M |
| 15 | BDX | Becton, Dickinson and Company | 18 | +$57.2M |
| 16 | GILD | Gilead Sciences, Inc. | 18 | +$32.1M |
| 17 | ISRG | Intuitive Surgical, Inc. | 18 | $-21.4M |
| 18 | WAT | Waters Corporation | 18 | +$3.5M |
| 19 | IDXX | IDEXX Laboratories, Inc. | 17 | $-60.6M |
| 20 | MCK | McKesson Corporation | 17 | +$26.1M |
Most Widely Held Healthcare Stocks
| # | Stock | Company | Institutional Holders | Total Value |
|---|
| 1 | JNJ | Johnson & Johnson | 288 | $9.0B |
| 2 | LLY | Eli Lilly and Company | 265 | $8.9B |
| 3 | ABBV | AbbVie Inc. | 261 | $4.4B |
| 4 | MRK | Merck & Co., Inc. | 240 | $4.5B |
| 5 | AMGN | Amgen Inc. | 211 | $2.7B |
| 6 | ABT | Abbott Laboratories | 197 | $1.7T |
| 7 | PFE | Pfizer Inc. | 190 | $1.5T |
| 8 | UNH | UnitedHealth Group Incorporated | 178 | $3.2B |
| 9 | TMO | Thermo Fisher Scientific Inc. | 169 | $3.1B |
| 10 | BMY | Bristol-Myers Squibb Company | 154 | $2.0T |
| 11 | SYK | Stryker Corporation | 143 | $1.4B |
| 12 | MDT | Medtronic Plc | 136 | $1.9T |
| 13 | GILD | Gilead Sciences, Inc. | 136 | $1.9B |
| 14 | DHR | Danaher Corporation | 128 | $1.7B |
| 15 | ISRG | Intuitive Surgical, Inc. | 127 | $2.2B |
| 16 | MCK | McKesson Corporation | 112 | $754.5M |
| 17 | CVS | CVS Health Corp. | 111 | $1.9T |
| 18 | VRTX | Vertex Pharmaceuticals Incorporated | 96 | $1.3B |
| 19 | CI | Cigna Corporation | 85 | $660.9M |
| 20 | EW | Edwards Lifesciences Corporation | 83 | $1.3T |
Data sourced from SEC 13F filings for Q3 2026. Filings are delayed up to 45 days after quarter end.